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ABSTRACT
We determined the molecular mechanism of cell
death response by MutS homologs in distinction to
the repair event. Key protein–DNA contacts differ in
the interaction of MutS homologs with cisplatinated
versus mismatched DNA. Mutational analyses of
protein–DNA contacts, which were predicted by
molecular dynamics (MD) simulations, were perfor-
med. Mutations in suggested interaction sites can
affect repair and cell death response independently,
and to different extents. A glutamate residue is iden-
tified as the key contact with cisplatin-DNA. Mutation
of the residue increases cisplatin resistance due to
increased non-specific DNA binding. In contrast,
the conserved phenylalanine that is instrumental
and indispensable for mismatch recognition during
repair is not required for cisplatin cytotoxicity.
These differences in protein–DNA interactions are
translated into localized conformational changes
that affect nucleotide requirements and inter-subunit
interactions. Specifically, the ability for ATP binding/
hydrolysis has little consequence for the MMR-
dependent damage response. As a consequence,
intersubunit contacts are altered that most likely
affect the interaction with downstream proteins. We
here describe the interaction of MutS homologs with
DNA damage, as it differs from the interaction with a
mismatch, and its structural translation into all other
functional regions of the protein as a mechanism
to initiate cell death response and concomitantly
inhibit repair.
INTRODUCTION
Mismatch repair (MMR) proteins contribute to the initiation
of cell death in response to DNA damage (1–3). Defects in
these proteins signiﬁcantly increase carcinogenesis, the toler-
ance to chemotherapy and clonal selection of cancer cells after
treatment.
Different hypotheses have been put forward to explain the
MMR-dependent cell death pathway (2). ‘Futile repair cycles’
entail repetitive repair attempts of damage-containing DNA
that occur on the ‘normal’, undamaged strand. This mecha-
nism requires replication across the damage to generate a
mismatch. Abortive repair attempts and persistent DNA
damage would result in strand breaks as the factual initiators
of cell death. Functional repair activity of the MMR proteins
is a prerequisite for this proposed mechanism. In contrast, the
damage-signaling hypothesis suggests the recruitment of
proapoptotic downstream proteins by MMR proteins and
the direct initiation of cell death. This mechanism can be con-
sidered repair-independent, though individual protein func-
tions may be overlapping for both pathways. Results from
our laboratory and others provide ﬁrst evidence that the repair
function is not required for MMR-dependent cisplatin cyto-
toxicity (1,4,5). MMR proteins interact with an intricate
network of proteins involved in cell cycle checkpoint and
apoptotic pathways, among which are p73, ATM, CHK2,
BRCA1 and PCNA (6), which provides another piece of
evidence suggesting that MMR proteins may play a direct
role in drug cytotoxicity.
Both hypotheses for MMR-dependent drug cytotoxicity are
based on the ability of the mismatch recognition protein, MutS
and its eukaryotic homologs (MSH) to recognize damage-
containing DNA, and initiate appropriate responses. For futile
repair cycles, the proteins would always recognize a mismatch
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would recognize the DNA damage, and, possibly, as a distinc-
tion to mismatch binding, initiate cell death. The crystal struc-
tures of MutS in complex with mismatched DNA demonstrate
that the presence of DNA introduces considerable conforma-
tional changes in the protein (7–9). It was proposed that the
ﬂexibility of DNA and an induced ﬁt upon binding are pivotal
for mismatch speciﬁcity. A 60  DNA bend that is introduced
at the site of the mismatch, is facilitated by intercalation of
a conserved phenylalanine residue. This residue is provided
by only one of the subunits (A) of the MutS homodimer
(corresponding to MSH6 in the eukaryotic protein) (7–12).
Base-stacking interactions of the Phe residue position the mis-
matched base for hydrogen bond interactions with a conserved
glutamate. The phenylalanine and glutamate residues provide
the only mismatch-speciﬁc contacts between MutS and mis-
matched DNA. These speciﬁc interactions with mismatched
DNA introduce conformational changes into the protein as
key steps in the initiation of repair. It is likely that distinctly
different interaction patterns with DNA damage contribute to
and determine the induction of different pathways, such as
celldeath.
Defective MMR was shown to result in a 2- to 4-fold
increase in tolerance to the chemotherapeutic agent cisplatin,
which contributes signiﬁcantly to the failure of cancer therapy
(2,13–15). MMR defects in ovarian cancer have recently been
associated with a decreased efﬁcacy of cisplatin therapy (16).
A molecular understanding of this correlation is clearly
warranted to improve current treatment measures for cancer
patients.
We investigated the molecular mechanism of protein–DNA
damage interactions as a key element in MMR-dependent
drug cytotoxicity. Increased DNA rigidity of cisplatin-
adducted DNA (CDDP-DNA) and distinct protein–DNA con-
tacts result in a damage-speciﬁc binding pattern by MSH
proteins. A conserved glutamate residue is instrumental in
the recognition of CDDP-DNA and its cytotoxicity. A muta-
tion in this residue increases overall, non-speciﬁc DNA
afﬁnity that interferes with cisplatin cytotoxicity. In contrast,
a mutation of the phenylalanine demonstrated that this
residue is dispensible for cisplatin cytotoxicity, while it was
shown to be absolutely required for the interaction with mis-
matched DNA and proﬁcient repair. We illustrate the biologi-
cal signiﬁcance of the individual contacts, and for the ﬁrst
time demonstrate that distinct MSH-CDDP-DNA interactions
separate cell death response from repair. These distinct
protein–DNA contacts are translated throughout the protein
into localized conformational alterations that amplify the
distinction between cell death response and repair. Our data
signiﬁcantly impact the mechanistic understanding of MMR-
dependent response to chemotherapy.
MATERIALS AND METHODS
Computational modeling
The simulation of the G/T mismatch is based on the X-ray
structure of Escherichia coli MutS in complex with heterodu-
plex DNA (7). Hydrogen atoms were added using the hbuild
facility of CHARMM (17). The CHARMM force ﬁeld was
used for the entire complex with additional parameters based
on pre-existing cisplatin parameters (17,18). This force ﬁeld
has been extensively parameterized for a wide range of bio-
logically important molecules, including nucleic acids, amino
acids, lipids and some small-molecule ligands. The platinated
DNAstructurewasbuiltusingthemismatchasatemplate.The
cross-linked structure was ﬁtted into the binding pocket to
maximize the structural overlap with the mismatched DNA
structure, followed by rotations and translations to minimize
the energy of the unrelaxed structure using the coordinate
manipulation andenergyminimization facilitiesofCHARMM
(17). The structure was fully solvated with TIP3P water in a
cubic box using the visual molecular dynamics (VMD) pack-
age (19). The fully solvated simulation was performed with a
2.0 fs timestep using SHAKE on all bonds to hydrogen atoms,
and with Particle Mesh Ewald as implemented in NAMD (20).
The simulation protocol consisted of 100 ps of free solvent
equilibration with ﬁxed solute, followed by 400 ps of full
unrestrained equilibration, and 1.6 ns of production. During
the unrestrained equilibration and the production simulation,
all atoms in the complex and the solvent are allowed to move
freely. As a result, for example, the DNA can bend freely and
the protein side chains can reorient. The angles were calcu-
lated with the trajectory analysis tools in VMD using the
backbone atoms in the terminal and central amino acids
after the equilibration period (19). The conformational anal-
yses were performed using VMD and CHARMM. After 2 ns,
the unplatinated mismatch interaction scheme was essentially
unaltered from the X-ray, and is not discussed. As a control, an
additional simulation was performed of a platinated G/T mis-
match using the same protocol. The conclusions from both
simulations are similar, although the magnitude of distant
conformational changes is smaller in the G/T simulations.
Modeling alone at present does not reveal any signiﬁcant
differences between the binding in the G/C and G/T interac-
tions. In the G/T simulations no structure (sampled every 2 ps)
has an RMSD of more than 2.1 s from the X-ray structure,
excluding those residues that are undeﬁned in the crystal struc-
ture. All the platinated structures are within 2.8 s of all the
structures sampled in the mismatch simulation, including
the residues undeﬁned in the X-ray structure (data not
shown). The simulation of the mutant MutS-E38A structure
was performed using the same methodology after the com-
putational mutagenesis was performed. The mutation was
introduced using the wild-type structure with hydrogen
atoms as a template. The alanine side chain was built
upon the original glutamate side chain, and the entire structure
was subjected to 500 steps of steepest descent minimiza-
tion with an r-dependent dielectric to locally minimize the
structure.
Protein purification
The puriﬁcation of E.coli MutS was performed as described
previously (21). Brieﬂy, cells harboring the expression
plasmid were lysed by pressure. His-tagged MutS in the
supernatant was selectively isolated by ion chelating chro-
matography. MutS-containing fractions were pooled and
further puriﬁed by Heparin Sepharose. The protein eluate
was concentrated, aliquoted and frozen in 30% glycerol
until needed.
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DNA was reacted with cisplatin according to the method
of Mello et al. (22). Brieﬂy, a single-stranded DNA oligomer
was mixed with 1.2 equivalents of cisplatin in 3 mM NaCl and
1m MN a 2HPO4 (pH7.4) and incubated at 37 C for 16 h.
Unreacted cisplatin was removed by extensive dialysis against
deionized water. The DNA was then lyophilized and resus-
pended in deionized water to desired concentration. The
sequence of the DNA used in the reaction is 50-ACCTGTC-
TGGCAACACTGTCACCGTCGTAT-30. The oligomer was
annealed to the complementary strand to produce homoduplex
double-stranded DNA or to the oligonucleotide with the
sequence 50-ATACGACGGTGACAGTGTTGCTAGACAG-
GT-30 to produce a single G-T mismatch opposite the site
of platination.
DNA binding assays
DNA binding afﬁnities were determined by measuring the
change in ﬂuorescence anisotropy of DNA duplexes in which
one strand was labeled with ﬂuorescein at the 50 end. The
data were collected using a Saﬁre II microplate reader with a
ﬂuorescence anisotropy module (Tecan) with excitation and
emission wavelengths of 490 and 525 nm, respectively. To
ensure equilibrium binding, the concentration of DNA was
kept at least 20-fold below the observed Kd for binding and
the concentration of MutS protein was titrated in the range of
5-fold below to 5-fold above the Kd. The dissociation con-
stants were calculated by ﬁtting the data to a model of single
site binding (Fbound ¼ [MutS]/Kd + [MutS]). Each experiment
was the average of at least four individual measurements.
Genetic assays
Treatment with cisplatin and cell survival assays were per-
formed as described before (1). The IC50 values and 95%
conﬁdence limits were obtained by quadratic curve ﬁtting,
as described (1,23). Mutation rate determinations based on
ﬂuctuation tests have been described (1,12).
RESULTS
The structural model of MutS in complex with
CDDP-DNA and prediction of interactions
The understanding of MMR-dependent damage-signaling
requires knowledge of the structural aspects of damage recog-
nition. No structural information is available for the interac-
tion between MutS homologs with any DNA damage. We
therefore performed molecular dynamics (MD) simulations
to obtain indications for the structural and molecular aspects
of the E.coli MutS-(1,2)GpG cisplatin crosslink complex. The
structural model is based on the crystal structure of DNA
containing a single (1,2)GpG cisplatin crosslink (24,25) built
into the crystal structure of E.coli MutS (7,9). The mismatched
DNA in the MutS crystal structure was used as a template. The
structural model of MutS in complex with CDDP-DNA is
shown in Figure 1.
We used this MutS-CDDP-DNA model and snapshots
obtained throughout the simulation to predict individual
protein–DNA interactions. Figure 2 displays protein–DNA
hydrogen bonds that were maintained for more than 90% of
the simulation time. The hydrogen bonding pattern is stable,
and no signiﬁcant transient interactions are observed at equi-
librium. The structural model with CDDP-DNA demonstrates
protein–DNA interactions that resemble the binding pattern
described for the individual interactions of MutS with ﬁve
different mismatches (Figure 2, italics) (9). The principle
interactions are hydrogen bonds. Most contacts with CDDP-
DNA are provided by domain I of subunit A (corresponding to
eukaryotic MSH6) and the clamp domain IV of subunit B
(corresponding to MSH2), similar to the interaction with mis-
matched DNA (7–9). Few unique contacts with CDDP-DNA
are identiﬁed (subunit A: T56, Y79; subunit B: N468, A469,
Q493); none of these newly gained contacts are conserved
among species. Other contacts are provided by residues
described previously for the interaction with mismatched
DNA (7–9), though the location with respect to the DNA
damage may differ (Figure 2, e.g. K496, R108, R500).
Biological significance of individual backbone contacts
between MutS and CDDP-DNA
We performed a mutational and genetic analysis of key
protein–DNA contacts predicted to be signiﬁcant for the
Figure 1. The structural model of E. coli MutS—CDDP-DNA. MutS in com-
plex with a 16mer oligonucleotide duplex containing a single (1,2) GpG cis-
platin adduct. The adduct cross-links the guanines at position 8 and 9 of one
DNA strand. Coloring distinguishes domain structure, with: blue (subunit A)/
purple (subunit B): mismatch binding domain I; green: connector domain II;
yellow: core domain III; orange: clamp domain IV and red: ATPase/dimeriza-
tiondomainV.DNAisshowninlightanddarkpurple.Thesymmetryaxisofthe
dimer runs vertical through the structure.
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predicted to contact DNA were introduced into the genes
expressing MSH protein(s) (Figure 2, Table 1). For this pur-
pose, the yeast complex of MutS homologs (MSH2/MSH6)
was analyzed. The amino acid sequences of MutS homologs
are highly conserved among species, which allows the anal-
ysis of homologous residues in different systems. The advan-
tage of the eukaryotic MutS homologous proteins is their
heterodimeric, rather than homodimeric nature, which allows
the separate analysis of each subunit. Results on cell survival
after cisplatin exposure were compared to the mutator phe-
notype associated with the individual mutation (Table 1). The
mutation rate, as an indicator for the mutator phenotype, was
determined using two well-characterized reporter systems (1).
The LYS2-A14 reporter detects frameshift mutations in an A14
nucleotide run. The forward reporter CAN1 primarily monitors
base substitutions in a MMR-deﬁcient background. Cells
defective in msh2 and msh3 msh6, respectively, display a
strong mutator phenotype in both systems (Table 1; msh2:
970- and 32-fold, respectively; msh3msh6: 1600- and 25-
fold, respectively). This genetic defect can be complemented
by plasmid-based expression of wt genes. As a measure for
drug cytotoxicity, dose-dependent cell survival after cisplatin
treatment was monitored. The IC50 values were determined by
quadratic curve ﬁtting (1). Defects in msh2 and msh3 msh6,
respectively, typically result in a 2- to 4-fold increase in
resistance to the drug (14,15), which is conﬁrmed by our
data [Table 1; msh2: 2.4-fold; msh3msh6: 1.8-fold, non-
overlapping conﬁdence limits (CL) with wild-type]. Mutations
were introduced into the MSH2 and MSH6 gene, according to
predicted protein–cisplatinated DNA interactions (Figure 2),
to determine their potential signiﬁcance for cisplatin cytotoxi-
city or repair. It has previously been demonstrated (data not
shown, 12) that mutant genes are expressed at similar levels as
wild-type.
Mutations in the putative backbone contacts affect either
damage response (as measured by the IC50 for cisplatin expo-
sure) or repair (mutation rate), or both. Several mutants that
demonstrate uncorrelated effects on cytotoxicity and repair
have been identiﬁed:
Cisplatin tolerance, weak effect on repair. Mutation
MSH6-K848A conveys no mutator phenotype in the frame-
shift reporter, and an intermediate mutator phenotype in the
base substitution reporter system (18-fold, compared to
25-fold for the knockout). This result per se indicates a func-
tional differences in the repair of different mismatches; the
residue appears to have functional signiﬁcance only for the
Figure 2. Diagram of MutS interactions with CDDP-DNA. Colors distinguish
interactions from the individual domains and correspond to Figure 1. Light
blue: domain I, subunit A (MSH6), orange: domain IV, subunit A; purple:
domainI,subunitB(MSH2),red:domainIV,subunitB.Residuestestedherein
areunderlined.Romannumbersrefertotheeffectgroupdescribedinthetext.+
and   describe whether a mutation in this residue results in a significant effect
on cisplatin cytotoxicity (compare to Table 1).
Table 1. Non-specific protein–DNA interactions in cisplatin cytotoxicity and MMR
E.coli S.cerevisiae IC50 [mM cisplatin] Mutation rate in LYS2-A14
a Mutation rate in CAN1
IC50 CL -fold MR 10
 6 CL 10
 6 -fold MR 10
 6 CL 10
 6 -fold
Dmsh3msh6 430 340–510 1.8 3000 860–11 000 1600 5.0 4.6–8.0 25
MSH6 wt 240 220–260 1 1.9 0.7–3.5 1 0.2 0.03–00.3 1
K496 MSH6-K848A 380 290–470 1.6
b 1.4 0.8–8.5 0.7 3.5 2.2–4.4 18
R108 MSH6-R412A 300 240–350 1.3 2800 970–3800 1500 4 3–5 20
R500 MSH6-R852A 300 260–340 1.3
b 9.1 6.5–15 5 0.9 0.5–2.2 4.5
Dmsh2 360 330–390 2.4 620 530–1800 970 15 11–19 32
MSH2 wt 150 130–170 1 0.64 0.4–1.0 1 0.47 0.37–30.66 1
K496 MSH2-K564A 230 230–240 1.5
b 430 320–750 670 6.6 5.7–7.5 14
E.c.: E.coli;I C 50: shown are means and standard deviations from at least three independent experiments. MR: mutation rate, CL: 95% confidence limits; -fold: in
comparison to wild-type (italics).
aAs described in (1).
bNon-overlapping confidence limits with wild-type; indicates statistically significant difference.
cAs designated from crystal structures with mismatched DNA (9) and predictions from structural model described herein.
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cisplatin cytotoxicity, with overlapping conﬁdence limits of
IC50’s with the complete knockout strain (Table 1), and hence
increases cisplatin tolerance signiﬁcantly. The residue is
located in the clamp domain of MSH6 (E.coli residue K496).
According to the simulation, this residue interacts with the
DNA backbone at a considerable distance (7 nt apart), and
on the opposite strand to the platinated site (Figure 2). This
mutant suggests that contacts distant from the site of damage
may gain functional signiﬁcance when compared to mismatch
recognition. We demonstrate here that a point mutation can
signiﬁcantly increase the resistance to cisplatin, independent
of its effect on repair.
Small effects on cisplatin cytotoxicity, impaired repair.
Residue R108 in MutS (MSH6-R412) affects the repair activ-
ity, but displays a weak or intermediate effect on cisplatin
sensitivity. This residue is predicted to contact the phosphate
backbone immediately 30 to the cisplatinated GpG crosslink
(Figure 2). MSH6-R412A increases cisplatin tolerance 1.3-
fold, with conﬁdence limits overlapping with the wild-type
and knockout strain, indicating an intermediate or week che-
motolerant phenotype (Table 1). In contrast, the mutation
results in a mutator phenotype that is indistinguishable from
the complete knockout strain (1500-fold increase in LYS2,
20-fold in CAN1, Table 1). This result suggests that the elim-
ination of this putative interaction by mutation is not sufﬁcient
toabrogateMMR-dependentdamageresponseentirely.Again,
this demonstrates that close vicinity or the distance to the
lesion is not indicative of the biological signiﬁcance of
protein-CDDP-DNA interactions. The distance is formally
deﬁned as geometric distance between contact and cross-
linked site. The R412A demonstrates no obvious correla-
tion between effects on cisplatin cytotoxicity and MMR.
In addition to the R412A alteration, a mutation in the nucleo-
tide binding motif of MSH2 (G693A in yeast) shows lack of
functional correlation between repair and cisplatin cytotoxi-
city (1,4). These results demonstrate that the elimination of
certain protein–DNA contacts can prevent repair of replication
errors, but retain some cisplatin cytotoxicity.
Small effects on both cisplatin cytotoxicity and repair.
Mutation MSH6-R852A does not affect damage response or
repair signiﬁcantly. Though both the crystal structure and the
structural model suggest that this residue provides a protein–
DNA interaction, this contact does not contribute signiﬁcantly
to either repair (5-/4.5-fold increase in mutation rate) or
damage response to cisplatin (1.3-fold increase, overlapping
conﬁdence limits with wild-type). MMR deﬁciency results in
a relatively weak resistance phenotype to cisplatin in a back-
ground where other repair pathways, including those process-
ing cisplatin adducts, are proﬁcient. The IC50 is typically 2- to
4-fold elevated. Though this increase has important implica-
tions for the failure of chemotherapy, demonstrating func-
tional signiﬁcance can be challenging. An effect of mutation
MSH6-R852A on cisplatin response cannot entirely be
excluded.
Increased cisplatin tolerance, increased repair deficiency.
Mutation MSH2-K564A (K496, Domain IV/B, Figure 2)
affects both cisplatin cytotoxicity and MMR. This residue
is expected to form hydrogen bonds with the phosphate
backbone in close vicinity to the adduct (Figure 2). The
IC50 for cisplatin cytotoxicity is signiﬁcantly elevated com-
pared to wild-type (1.5-fold; non-overlapping conﬁdence lim-
its with wild-type), verifying the functional signiﬁcance of this
predicted interaction. On the other hand, the conﬁdence limits
are also non-overlapping with the knockout, overall suggest-
ing an intermediate effect on cisplatin cytotoxicity, similar to
R412A. The mutation results in a strong mutator phenotype in
bothreportersystems(Table 1). This resultdemonstrates thata
point mutation can affect both repair activity and drug
cytotoxicity.
The identiﬁcation of mutations that show no correlation
between the functional requirements for damage response
and repair supports the hypothesis that MMR-dependent
cisplatin cytotoxicity is initiated independently of the repair
event.
Altered base-specific contacts with
CDDP-DNA—Phenylalanine 36
Our structural model of MutS with CDDP-DNA predicts a
considerable dislocation of residues that provide indispensable
contacts for mismatch recognition (Figure 3). In the structure
with mismatched DNA, a conserved phenylalanine residue
(E.coli F36/subunit A, MSH6-F337) base-stacks with one
base of the mismatch, this is the most important direct inter-
action with the mismatch. In the interaction with CDDP-DNA,
the Phe residue is not parallel to either one of the cross-linked
guanine bases. This dislocation prevents base-stacking or
other interactions with the CDDP-DNA (Figure 3). The pres-
ence of a thymine mismatched with the cross-linked guanines
does not alter the location of the Phe signiﬁcantly (computa-
tional data not shown). The dislocation in the protein–DNA
complex is hence a result of the DNA damage introduced by
CDDP. This prediction that the Phe does not signiﬁcantly
contribute to interactions with CDDP-DNA suggests that a
mutation of this residue will not affect CDDP cytotoxicity.
The mutational analysis (MSH6-F337A) conﬁrms this pre-
diction and demonstrates differential requirements for the Phe
residue in cisplatin cytotoxicity and repair (Table 2). As sug-
gested by the dislocation of the Phe residue from CDDP-DNA
(Figure 3), the cisplatin cytotoxicity is not affected by the
F337A mutation. In comparison to wild-type MSH6, the
MSH6-F337A mutation lowers the IC50 to 180 mM as com-
pared to 240 mM for wild-type. This signiﬁcant increase in
cisplatin sensitivity might be due to the elimination of steric
hindrances, and replacement of the side chain with a consid-
erably less bulky one. Alternatively, the impediment of inter-
actions with mismatch may result in an increase in free protein
that is available for the interaction with DNA damage, and
hence result in the observed increase in cisplatin sensitivity.
We have performed this experiment and puriﬁed the
MutS-F36A mutant and performed anisotropy measurements
in analogy to the data presented for E38A (Table 3; Figure 4).
Surprisingly, the F36A mutant did not exhibit binding to either
DNA or cisplatinated DNA. To reconcile these data with our
experimental analysis of cisplatin cytotoxicity, we hypo-
thesized that this might be due to the mutant protein
being a double mutant, as the E.coli protein consists of a
MutS homodimer, rather than the eukaryotic Msh2/Msh6
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‘structure–function heterodimer’, in which both subunits are
non-equivalent. The phenylalanine residue in subunit B is in
no direct interaction with DNA. To determine, if a mutation
in this residue in subunit B could nonetheless alter the protein
structure sufﬁciently to explain the lack of any DNA binding
activity, we modeled this mutation into the E.coli protein (in
analogy to E38A, Figure 4). We note that in the X-ray struc-
ture, and the modeled structures, the F36 residue resides
in subunit B is in a beta-hairpin structure. This hairpin
contains Arg32, which provides one of the few protein–DNA
interactions (Figure 2; not conserved in eukaryotic protein).
We hypothesized that the F36 in subunit B may play a struc-
tural role in maintaining non-speciﬁc interactions between
subunit B and DNA. Using structures from the ends of both
the simulations of mismatched DNA and mismatched DNA
with cisplatin, the interaction energies between DNA and each
residue of the protein were calculated in a pseudovacuum, and
Arg32 and Arg500 had the most important non-speciﬁc inter-
actions. The importance of these two interactions was robust.
These results prompted simulations of the single and double
F36A mutants to see if there were conformational changes
consistent with our hypothesis observable on a nanosecond
time-scale. The simulations need to start with DNA-bound,
and are not capable of observing unbinding of DNA, nor large
conformation changes, due to the time-scale of the simulation.
However, it is possible to observe local conformational
changes, which would be sufﬁcient to test our hypothesis.
As a result of this simulation, we observed that within one
nanosecond of the simulation, the R32-DNA interaction was
mostly lost in the double mutant, but not in the single mutant.
Figure3.Base-specificinteractionsofwild-typeMutSwithCDDP-DNA.Goldsphere:cisplatinum.ShownarePhe36andGlu38(E.coli)intheirorientationtowards
thecross-linkedguanines.HydrogenbondsbetweenGlu38andtheguaninesareindicated.(A)BothhydrogenbondsthatcanbeformedbetweenGlu38andeitherone
of the cross-linked guanines. (B) and (C) The alternate hydrogenbonds formed between Glu38 and one of the cisplatin-cross-linked guanines. The local distortions
induced by either conformation are indicated.
Table 2. Base contacts of protein–DNA interactions in cisplatin cytotoxicity and MMR
E.coli S.cerevisiae IC50 [mM cisplatin] Mutation rate in LYS2-A14
a Mutation rate in CAN1
IC50 CL -fold MR 10
 6 CL 10
 6 -fold MR 10
 6 CL 10
 6 -fold
F36 MSH6-F337A 180 150–200 0.8
b 990 610–1600 520 ND
c
E38 MSH6-E339Q 400 380–410 1.7
b 44 32–67 23 3 1.4–4.6 15
E.c.: E.coli;I C 50: shown are means and standard deviations from at least three independent experiments. MR: mutation rate, CL: 95% confidence limits; -fold: in
comparison to wild-type (italics).
aAs described in (1).
bNon-overlapping confidence limits with wild-type; indicates statistically significant difference.
cThe F337A was shown to result in a strong mutator phenotype in the CAN1 reporter system, indistinguishable from the knockout strain (10). ND: not determined.
Table 3. Dissociation constants for the interaction of MutS with mismatched
and platinated DNA
MutS Kd [mM protein]
G/C G/T CP-GpG/CC CP-GpG/CT
Wild-type 2.7 ± 0.087 0.1 ± 0.008 1.3 ± 0.065 0.36 ± 0.046
E38A 0.61 ± 0.058 0.16 ± 0.058 0.6 ± 0.078 0.2 ± 0.069
Numbers are mean values and standard deviations of at least four independent
experiments. Lesions present in the DNA are indicated.
2178 Nucleic Acids Research, 2006, Vol. 34, No. 8This supports our hypothesis that the F36A mutation in the
second subunit B (‘Msh2’) of the E.coli protein alters the
protein structure sufﬁciently to destabilize the protein–DNA
interaction sufﬁciently to eliminate all DNA binding, which
makes it impossible to biochemically determine the difference
between mismatch and cisplatin recognition.
Overall, the computational prediction of a lack of base-
stacking interactions is conﬁrmed by the biological experi-
ments. MSH6-F337A results in a strong mutator phenotype
that is indistinguishable from a complete knockout in MMR.
This result demonstrates the absolute requirement for the
Phe residue in MMR. Hence, the contact found to be most
important in the interaction with mismatched DNA does not
contribute to the interaction with CDDP-DNA and cisplatin
cytotoxicity.
Altered base-specific contacts with
CDDP-DNA—Glutamate 38
In the structural simulation with CDDP-DNA, a glutamate
residue (E.coli E38/subunit A; MSH6-E339) provides signiﬁ-
cant hydrogen bonds with both cross-linked guanines
(Figure 3A). The hydrogen bond containing the glutamate
residue switches readily between the two cross-linked gua-
nines in the simulation, although both guanines are always
in close contact to the glutamate (Figure 3A). Due to the
crosslink, the N7 position of the guanines is not available
for hydrogen bonding (26), and a change to the syn conforma-
tion that is observed for purine mismatches (9), is prevented.
Furthermore, the presence of the positive charge density from
the CDDP might be expected to reduce local electrostatic
repulsions between the DNA and nearby negatively charged
amino acid side chains, e.g. Glu38. Indeed, hydrogen bond
formation is predicted between the hydrogens of the N2 posi-
tionoftheguaninesandthe O-epsilonofGlu38(Figure 3A).In
the interaction with mismatched DNA, the intercalation of the
Phe residue re-orients the mismatched base for the interaction
with the Glu (9). With the missing Phe base-stacking, no
such reorientation of the bases is observed in the simulation
studies. The prediction from this observation is that different
contacts between the Glu and the CDDP-crosslink are estab-
lished, which are important for protein–DNA complex forma-
tion. To test this prediction, the consequences of a mutation
in MSH6-E339 for cisplatin cytotoxicity were analyzed. The
mutation confers a resistance phenotype indistinguishable
from the complete knockout strain (IC50 of 400 and 430 mM
for Dmsh3 msh6, Table 2). The presence of this Glu residue is
hence required for cisplatin cytotoxicity. The mutation results
in a weak, 23-fold increase in the frameshift mutation rate
(compared to 1600-fold for the knockout strain), and a more
signiﬁcant increase in base substitutions (15-fold, compared
to 25-fold for the knockout).
To investigate the structural consequences of a mutation
in the Glu residue, we simulated the E38A mutation in the
MutS-CDDP-DNA model (Figure 4). The number of putative
backbone contacts between the mutant MutS and CDDP-DNA
increases signiﬁcantly, so that there are more interactions with
MutS in the E39A mutation than in wild-type MutS (com-
putational data not shown). Strikingly, the phenylalanine
residue, which is dislocated and functionally dispensable in
the MutS wt-CDDP-DNA complex (Figure 3), provides a new
protein–DNA interaction in the mutant protein–DNA com-
plex.Inthe E38A-CDDP-DNAcomplex,thePheresidue base-
stacks with the base 1 nt 30 to the base pairing cytosine on
thestrand oppositetothecross-linkedguanines (Figure4).The
Phe residue base-stacks with Ade26, which disrupts the
A26–T7 base pairing and the base-stacking interactions
between A26 and G27. The base pairing of C6 and G27 is
preserved (Figure 4). These structural features predict that
the mutation of the glutamate residue would enhance DNA
binding (due to gained base-stacking interaction and an
increased number of contacts with the DNA backbone).
This potentially increased afﬁnity should be non-speciﬁc for
the damage (since the mutation eliminates the direct inter-
actions with the cross-linked bases, but gains backbone
contacts).
Puriﬁed E.coli MutS-E38A mutant protein was used to
directly evaluate the effects on DNA binding by ﬂuorescence
polarization (Table 3). The sequence of the 30mer DNA
oligomer was chosen to contain only one potential cisplatin
site (see Materials and Methods).
The binding afﬁnity of the mutant MutS-E38A was com-
pared to that of wild-type MutS. Increasing amounts of full
length wild-type and mutant MutS were incubated with the
indicated substrates. Protein–DNA interactions were deter-
mined by changes in ﬂuorescence anisotropy and the Kd of
interaction determined (Table 3). The wild-type MutS protein
recognizes CDDP-DNA; the afﬁnity is about 10-fold weaker
than binding to a mismatch (compare Kd hetero of 0.1 mM and
Kd CP-GpG/CC of 1.3 mM). The binding afﬁnity for CDDP-DNA
is improved when one of the cross-linked guanines is mis-
matched with a thymine (Kd CP-GpG/CT of 0.36 mM; Table 3).
The selectivity for mismatched over matched DNA is signiﬁ-
cantly weaker when the cisplatin adduct is present (Kd CP-GpG/
CC of1.3 mMand Kd CP-GpG/CT of0.36 mM;4-folddifference as
compared to 27-fold without cisplatin).
In comparison to wild-type MutS, MutS-E38A shows
strongly decreased speciﬁcity for mismatched DNA. This is
Figure 4. Base-specific interactions of MutS-E38A with CDDP-DNA. Gold
sphere: cisplatinum. The nomenclature for base pairs is the same as shown in
Figure 3. Phe36 and the Ala substituting for Glu38 are shown in yellow.
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binding afﬁnity for a G/T mismatch is largely unaffected
(Kd homo of 0.61 mM and Kd hetero of 0.16 mM). The afﬁnity
for homoduplex is only 3.8-fold lower than for heteroduplex
DNA. This increase in non-speciﬁc binding is consistent with
previously published data on the E38A and E38Q mutant
(21,27).
The mutant protein binds to CDDP-DNA with an
afﬁnity comparable to the one observed for homoduplex
DNA (Kd CP-GpG/CC of 0.6 mM and Kd homo of 0.61 mM;
Table 3). Similarly, the binding afﬁnity for a G/T mis-
match and mismatched CDDP-DNA is roughly the same
(Kd CP-GpG/CT of 0.2 mM and Kd hetero of 0.16 mM). The mutant
protein shows no speciﬁcity for binding to CDDP-DNA.
Conformational differences in the MutS complex with
cisplatinated DNA—ATPase domain
The bacterial MutS crystal structures together with exp-
erimental data revealed a highly coordinated series of intra-
molecular conformational changes that is essential for the
initiation of repair. These conformational changes are initiated
and controlled by the presence of DNA and nucleotide. The
presence of DNA is required to structurally order large parts
of the protein (7,9); concerted conformational changes that
follow, are associated with the consecutive and highly coor-
dinated binding and hydrolysis of ATP by both subunits (28–
35). Both of these events affect each other and are tightly
controlled. We hypothesized that the distinct protein–DNA
interactions described above alter the DNA and nucleotide-
dependent intramolecular conformational changes, and that
these different, lesion-dependent changes provide the driving
force for the initiation of different downstream events. To test
the suggestion of a correlation between DNA interaction, con-
formational changes and the concomitant induction of differ-
ent pathways, we compared the structure of MutS-mismatched
DNA to the model with platinated DNA and identiﬁed regions
of largest conformational differences between both structures.
Based on the structural model (Figure 1), we identiﬁed regions
of the protein that show largest deviations between the struc-
tures with mismatched and platinated DNA, respectively
(Table 4). Large scale changes were identiﬁed as protein
regions in which alpha carbon atoms were moved signiﬁcantly
(>7 s) in comparison to the crystal structure with mismatched
DNA. These changes are summarized in Table 4. Signiﬁcant
structural deviations are very localized and are observed in the
ATP binding/hydrolysis motifs (N2-motif, Walker A motif,
RH) (7,8), and the variable and disordered loop regions of
the MutS protein. The overall functional asymmetry between
both subunits is maintained in the conformational changes.
Subunit B, corresponding to eukaryotic MSH2, is more
severely affected than subunit A (eukaryotic MSH6). While
the ATP binding domain (Walker A motif) is affected in
subunit B, no alteration in this motif is observed in subunit
A (Table 4). The structural model presented here suggests that
ATP binding by MSH2 may be impaired in the complex with
platinated DNA due to the conformational dislocation of the
binding motif. Hence, a mutation in this subunit (G693A in
yMSH2) will not affect damage response. This is in consis-
tence with previous data from our laboratory (1) and others
(36). In contrast, the N-2 nt binding motif is affected in both
subunits. This motif is part of the composite ATPase site,
which undergoes conformational changes during the coordi-
nated cycle of ATP binding and hydrolysis performed by both
subunits (9,28,31). The N-2 motif is implied to interact with
the g-phosphate of the nucleotide bound to the neighboring
subunit, which thereby acts in trans in ATP hydrolysis (9).
Mutations in this motif decrease ATP binding and hydrolysis
in the bacterial protein [Table 5; (28)]. The conformational
changes that are associated with the ATP binding/hydrolysis
cycle are ampliﬁed throughout the MutS/MSH protein (28,31).
We performed mutational analyses of the highly conserved
serine residue in the N-2 motif in both eukaryotic subunits,
MSH2 and MSH6, and addressed the question of how these
mutations affect cisplatin response compared to MMR. The
mutation in the MSH2 protein, S742A, does not alter the
response to cisplatin, and the IC50 is identical with wild-type
response (Table 5). This is consistent with the fact that the
ATPase domain of subunit B/MSH2 is primarily affected and
structurally altered by binding to cisplatinated DNA, poten-
tially alleviating any functional requirement (Table 4). The
homologous mutation in MSH6 (S1036A) results in an inter-
mediate effect, increasing the IC50 1.7-fold above wild-type
(Table 5). This result reﬂects the less pronounced structural
changes in this subunit upon interaction with cisplatinated
DNA. Mutations in both MSH2 and MSH6 result in an
increased mutator phenotype (Table 5). This increase in the
mutation rate is likely associated with the reduced ATPase
activity of the mutant proteins, as illustrated by the 2-fold
reduced Kcat/Km of the single mutants, and the 33-fold reduced
activity of the double mutant (Table 5). These data demon-
strate that both N-2 motifs contribute to ATP hydrolysis in the
eukaryotic MSH2/MSH6 heterodimer, and this activity is
required for functional MMR. In contrast, the activity of
the composite ATPase sites is largely dispensable for damage
response.ThemissingeffectoftheMSH2mutationondamage
response reﬂects and conﬁrms that the ATP binding and
hydrolysis motifs of this subunit are structurally altered, pre-
venting nucleotide binding and hydrolysis, while the MSH6
motifs are less affected. This difference between both subunits
Table 4. Largest conformational changes when comparing MutS complexes with mismatched and cisplatinated DNA
Domain Subunit A (‘MSH6’) Affected regions Subunit B (‘MSH2’) Affected regions
III: Core 287–288 Variable loop 283–289 Variable loop
V: ATPase 668–669 Next to N-2 motif 585–596 RH motif, interdomain
Dimerization 622–623 ATP binding (Walker A)
660–661 Disordered loop (yD735)
668–669 N-2 motif
Large conformational changes are defined as Ca RMSD’s >7 s. Numbers depict amino acid residues in E.coli MutS (7, 9s).
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tional aspects of the MSH proteins is preserved in damage
response, though the contribution of each subunit is altered.
The weaker effect on the MSH6 subunit may be attributed to
the suggestion that the heterodimer exists as ATP-MSH-ADP,
suggestively as MSH2-ADP/MSH6-ATP in the absence of
DNA (29,37), with ATP already bound to MSH6 prior to
the interaction with DNA.
It was previously shown that the MSH-DNA complex dis-
sociates in the presence of ATP and the concomitant absence
of other co-factors. This reaction requires only ATP binding,
not hydrolysis. We postulated that if the cisplatinated DNA
alters the structure such that ATP is not required for cisplatin
cytotoxity, the addition of nucleotide will not affect the
protein–DNA interaction with the crosslink. The results of a
binding studytesting this hypothesis are shownin Table 6. The
addition of ATP to the G/T mismatch results in the typical
dissociation of the complex. In contrast, the nucleotide has
no effect on the binding of the cisplatinated matched DNA.
Binding to the cisplatinated, mismatched DNA shows a 2-fold
weakeningoftheprotein–DNAinteraction,which, however,is
not as strong as the one observed with the G/T mismatch.
These data demonstrate that ATP does not inﬂuence the
interaction between MutS and cisplatinated DNA, which is
in sharp contrast to the interaction with mismatched DNA,
and supports the cytotoxicity data from the mutational
analysis.
Conformational differences in the MutS complex with
cisplatinated DNA—Inter-subunit contacts
Another set of structural differences between the platinated
and mismatched protein–DNA complex involves the disor-
dered loop of subunit B (MSH2) and the variable loop in
both subunits. The disordered loop (residues 661–667 in
E.coli MutS), which directly precedes the N-2 motif, is not
traceable in the structure of the MutS-ADP complex (7,9);
this loop becomes ordered and traceable in subunit B
(MSH2) in the presence of a non-hydrolyzable ATP analog
(31). The same loop region in subunit A (MSH6, the
mismatch-interacting subunit) remains disordered. The
ordered loop in subunit B communicates the presence of
ATP (or its non-hydrolyzable analog) to the variable loop
region of domain II in subunit A (Figure 5, left). Both regions,
the disordered loop in subunit B/MSH2 and the variable loop
in subunit A/MSH6 undergo signiﬁcant dislocations in the
model that replaces the mismatched DNA with platinated
DNA (Figure 5). While in the crystal structure of TaqMuts
with ADP-BeF, a putative hydrogen bond connects the dis-
ordered loop in subunit B with arginine 267 of the variable
loop in subunit A, the disordered region in the cisplatin model
shows two major conformations. In one conformation, argi-
nine 667 (disordered) and asparagine 289 (variable) are in
close enough vicinity to form a hydrogen bond, similar to
that observed in the structure with mismatched DNA. How-
ever, this conformation exists only for 42% of the simulation.
In the second conformation both loop regions are distant, and
residuesare about 16sapart(Figure5,right). Theobservation
that the MutS-platinated DNA model assumes two different
conformations during the simulation—at least one of which
preventing inter-subunit interactions—argues that the loop–
loop contacts observed with mismatched DNA are not strong
enough and disrupted in the complex with cisplatinated DNA.
To test the signiﬁcance of the disordered loop for DNA dam-
age response, we mutated the conserved ﬁrst aspartate residue
in the loop region in both MSH2 and MSH6, and performed
cell survival studies. Table 7 demonstrates that a mutation in
the conserved aspartate residue in the ‘disordered’ loop region
does not affect cell survival after exposure to cisplatin. The
IC50 values for both MSH2-D735A (180 mM) and
MSH6-D1029A (160 mM) are indistinguishable from
the wild-type response (compare to Table 1). In contrast,
the mutation rates of Msh2-D735A and Msh6-D1036A
mutants are strongly elevated and indistinguishable from a
complete knockout (Table 7). This result suggests that the
disordered loop region is essential for the repair event, as
was implied by studies showing that the nucleotide-dependent
structural ‘ordering’ of this loop provides inter-subunit
interactions that are essential in the interaction with repair-
associated downstream proteins (31). In contrast, our experi-
mental data support the dislocation of this loop region in the
complexwithcisplatinatedDNA,aspredictedbythestructural
model (Figure 5), and the lack or alteration of inter-subunit
interactions.
DISCUSSION
This is the ﬁrst report to describe distinct structural features
of MSH-CDDP-DNA interactions and localized confor-
mational changes that depend on the nature of the lesion, as
Table 5. Effects of mutations in the N2-motif of the ATPase domains of MSH2 and MSH6
Allele IC50 [mM cisplatin] Mutation rate in LYS2-A14 Mutation rate in CAN1 ATPase
IC50 -fold MR 10
 6 -fold MR 10
 6 -fold Protein Kcat/Km
a
Msh2-S742A 170 ± 46 1 1300 2030 2.9 6.2 S742A/Msh6wt 0.5
Msh6-S1036A 310 ± 96 1.7 390 205 1.2 6 Msh2wt/S1036A 0.6
S742A/S1036A 0.03
aThe wild-type Kcat/Km was determined to be 1 (58). MR: mutation rate, -fold: in comparison to wild-type (see Table 1).
Table 6. Dissociation constants for the interaction of MutS with mismatched
and platinated DNA in the presence and absence of ATP
MutS Kd [mM protein]
G/C G/T CP-GpG/CC CP-GpG/CT
Wild-type 2.7 ± 0.087 0.1 ± 0.008 1.3 ± 0.065 0.36 ± 0.046
+ ATP 1.08 ± 0.72 0.67 ± 0.14 1.34 ± 0.58 0.74 ± 0.23
Fold change +2.5  6.7 1  2.1
Fold change when comparing dissociation constant with ATP to those without
the nucleotide for the same substrate.
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dependent cell death, and its autonomy from mismatch recog-
nition and repair. Individual putative interactions between
MutS and CDDP-DNA were determined by mutational anal-
ysis. Mutational analyses are aided by predictions made from
MD simulations (Figure 1). This approach has its limitations,
but in the absence of structural information, it is valuable in
predicting protein–DNA interactions that can be tested in the
experimental setting. Force ﬁelds similar to the ones described
here have been used to study the structure and dynamics of
nucleic acids and nucleic acid–protein complexes in a wide
variety of situations, e.g. in protein-mediated base-ﬂipping
(38), structural ﬂuctuations in RNA and DNA (39), the ener-
getic analysis of DNA structures (40) and the evaluation of
dynamics and energetics of modiﬁed DNA (41). The ability
of empirical force ﬁelds to model atomic level details of
biomolecular systems that include proteins, nucleic acids,
lipids and carbohydrates has recently been reviewed (42).
Results from our experimental data, herein and described pre-
viously (1), validate the predictions from the MD simulations
for the type of study described herein.
The ﬂexibility of DNA was previously suggested to be a
main contributor to the speciﬁcity of mismatch recognition.
This was supported by the observation that MutS provides
very few mismatch-speciﬁc interactions, and the majority of
contacts occur to the DNA backbone, making a speciﬁc ‘read-
out’ mechanism for each individual mismatch unlikely (8–10).
The interaction of MutS with mismatched DNA is rather a
general, ‘induced ﬁt’ mode, in which intrinsically destabilized
substrates are preferred (21). The presence of a mismatch by
itself does not cause any dramatic structural changes in DNA
(43–47). It, however, locally destabilizes the DNA, as deter-
mined by alterations in the melting temperature (48). This may
provide the additional ﬂexibility required for the speciﬁc
interaction with MutS. In the presence of MutS, a 60  kink
is introduced at the site of the mismatch. Recently, it was
proposed that a series of DNA bending, kinking and ultimately
unbending is required to initiate repair (49). Though the
unbending event still requires additional veriﬁcation, it is
clear that the induction of repair requires considerable ﬂexi-
bility of the MutS-DNA complex. In contrast, the 1,2-GpG
intrastrand crosslink introduced by cisplatination itself gener-
ates a kink in DNA (24,25,50). The structural features of this
kink resemble those found for the mismatched DNA in its
complex with MutS. Our data demonstrate that the cisplatin
adduct leaves the DNA considerably more rigid, and does
not allow the ﬂexibility observed for the mismatched DNA
(data not shown). The similarity of the cisplatin-induced DNA
bend may promote recognition by MutS (Table 3), but the
inﬂexibility of the adducted DNA may impair further down-
stream events that are directed towards repair. The increased
rigidity of CDDP-DNA in complex with MutS may be a
determining factor for the initiation of the cell death pathway.
The effect of other types of DNA damage that introduce
different local distortions remains to be determined and is
currently under investigation in our laboratory. In addition,
it was recently suggested that the substrate speciﬁcity
observed for MMR is provided not so much by the initial
protein–DNA interactions, but dramatically ampliﬁed by
downstream events, such as the excision event (51). Whether
Figure5.Schematicpresentationofthe‘disordered’loopofsubunitB/MSH2andthevariableloopofsubunitA/MSH6incomplexeswithmismatchedandplatinated
DNA.The‘disordered’loopisshowningreen,thevariableloopisshownasaspace-fillingmodel.(A)CrystalstructureofTaqMutSincomplexwithADP.beryllium
fluoride and mismatched DNA [(31), the only structure with a non-hydrolyzed ATP derivative], showing parts of the connector (green) and core (yellow) domains,
and the ATPase/helix–uturn–helix domain (pink). (B) Model of the E.coli MutS in complex with cisplatinated DNA, showing parts of the connector (green) and
core (yellow) domains, and the ATPase/helix–uturn–helix domain (pink). Arrows point at the closest distance between the variable loop (space-filling) of subunit
A/MSH6 and the ‘disordered’ loop (green) of subunit B/MSH2.
Table 7. Effects of mutations in the disordered loop of MSH2 and MSH6
Allele IC50 [mM cisplatin] Mutation rate in LYS2-A14 Mutation rate in CAN1
IC50 -fold MR 10
 6 CL 10
 6 -fold MR 10
 6 CL 10
 6 -fold
Msh2-D735A 180 ± 87 1.1 950 700–1400 1500 11 8.8–33 23
Msh6-D1029A 160 ± 25 0.89 300 140–1100 160 7.1 2.7–19 36
MR: mutation rate, CL: 95% confidence limits; -fold: in comparison to wild-type (italics).
2182 Nucleic Acids Research, 2006, Vol. 34, No. 8this is true for the binding to cisplatinated DNA remains to be
determined.
The structure of the MutS protein in complex with ﬁve
different mismatches identiﬁed a general binding mode (10).
The comparison of the MutS-CDDP-DNA model with the
structure containing mismatched DNA reveals most promi-
nent structural differences in the DNA binding domains I
and IV (Figure 1). Our functional analysis based on pre-
dictions of individual protein contacts with CDDP-DNA
(Figure 2) demonstrate that the general binding mode is
conserved in the interaction with CDDP-DNA. However,
the biological signiﬁcance of the protein–DNA backbone
contacts differs markedly (Table 1). A shift in the backbone
interactions with CDDP-DNA is likely to induce different
conformational changes throughout the protein (see below).
The location of residues that make speciﬁc interactions
with mismatches is signiﬁcantly distorted in the interaction
with CDDP-DNA (Figure 3: Table 2). In the structure with
mismatched DNA, a conserved Phe residue (F36 of subunit
Ai nE.coli) base-stacks with one of the mismatched bases
(8–10). This base-stacking interaction is critical for DNA
binding and repair activity; a mutation in this residue
abrogates mismatch recognition and repair (10–12,21,52).
The intercalation re-orients the mismatched base such that
Glu38 (E.coli) can form hydrogen bonds with the base.
This conserved residue contacts the N3 of pyrimidines and
N7 of purines. Mismatches containing purines enter this
interaction in the syn conformation (10). In contrast, no
intercalation of the Phe residue is predicted by the model
with CDDP-DNA (Figure 3), and experimental data conﬁrm
that this residue is not required in cisplatin cytotoxicity
(Table 2). Due to this missing base-stacking interaction, no
re-positioning of the guanine for hydrogen bonding with the
glutamate residue is observed.
The (1,2)GpG cisplatin adduct cross-links two adjacent
guanines via their N7 positions, leaving this position inacces-
sible for interactions with the Glu residue. In addition, the
crosslink prevents the transition to the syn conformation.
The Glu, instead, interacts with the N2 position of the cross-
linked guanines (Figure 3). The conservative mutation of this
Glu to a glutamine reduces cisplatin cytotoxicity (E339Q,
Table 2). A mutant protein bearing an E to Q change in
E.coli binds to homoduplex DNA with enhanced afﬁnity
(Table 3). At ﬁrst glance, the increased cisplatin resistance,
together with the increased DNA binding activity of the Glu
mutant appears counterintuitive. Though differences between
the bacterial and eukaryotic proteins cannot be excluded, the
DNA binding analysis (Table 3), together with the structural
simulation of the mutant protein (Figure 4, Supplementary
Figure 1), may explain this discrepancy.
The mutant protein gains base-stacking interactions of
Phe36 at a lesion-independent site (Figure 4), and increases
the overall number of protein-CDDP-DNA backbone contacts
(data not shown). This increased, non-speciﬁc binding may
be reinforced by the elimination of the repulsive, negative
charge. The binding afﬁnity for homoduplex DNA increases
disproportionately to the afﬁnity for CDDP-DNA (Table 3).
Hence, the mutant protein lacks any speciﬁcity for the recog-
nition of CDDP-DNA, and will bind to homoduplex DNA
with the same afﬁnity. This lack of selectivity may result in
increased recombinational bypass or translesion synthesis
(53), which is detected as an increase in cisplatin resistance.
Taken together, these data demonstrate that the Glu38
residue plays a signiﬁcant role in the interaction with
CDDP-DNA, the direct interaction with the cross-linked
bases and the re-positioning of protein–DNA contacts. Further
analysis is required that will determine whether the ﬁndings
of this report can be transferred to the interaction of MutS
with other types of DNA damage. These studies are underway.
As a result of different protein–DNA interactions that are
observed in the MutS-platinated DNA complex, distinct
conformational changes are transmitted throughout the protein
that differ from the complex with mismatched DNA, and are
localizedtotheATPasedomain,the disordered loopofsubunit
B/MSH2 and the variable loops of both subunits. These con-
formational changes will prevent ATP binding by MSH2 and
hydrolysis by both subunits. This is consistent with data
demonstrating that neither function is required for the induc-
tion of cell death after cisplatin exposure (1,36) (Tables 5 and
6). The dislocation of the disordered loop in subunit B/MSH2
and the variable loops results in an increased distance between
these loop regions, resulting in unstable inter-subunit interac-
tions (Figure 5; Table 7) which prevent signal transmission
between the ATPase domains and the DNA binding domains.
These missing inter-subunit contacts are predicted to result in
altered DNA release patterns and interactions with down-
stream proteins, likely factors that can lead to the initiation
of the cell death pathway, and at the same time hinder repair.
Whether this is provoked by the MSH-DNA complex present-
ing a ‘suicide or dead end complex’ with an increased lifetime
that prevents repair and hinders replication, or a dynamic
complex, is an important question and remains to be deter-
mined. Numerous direct interactions of MMR proteins with
proapoptotic proteins suggest a direct role in the initiation of
cell death and cell cycle checkpoint control in response to
certain DNA damage (54–56).
For a cell to be directed towards cell death response,
repair has to be inhibited or be otherwise impossible, and
proapoptotic proteins have to be recruited and activated.
We here present ﬁrst experimental data on the signals that
preferentially trigger MMR-dependent damage response,
and may result in the prevention of repair. We propose a
model for MMR-dependent damage response in which altered
DNA ﬂexibility and changes in protein–DNA interactions are
transmitted across the MSH protein via distinct conforma-
tional changes. These structural changes alter the nucleotide
requirements, which ultimately affect intermolecular contacts
involved in the recruitment of and interaction with down-
stream proteins. MMR in general is thought to act more
rapid than NER (57). Thus, the kinetics of MMR proteins,
together with the herein described response to DNA damage
may in addition to preventing MMR per se, provide an
impediment for other repair proteins, such as NER proteins,
to access the side of the lesion. This event would present yet
another contribution toward cell death and inhibition of
repair. Mutants in all functionally important regions of
the protein demonstrate a lack of correlation between the
functional requirements for cisplatin cytotoxicity and repair.
The identiﬁcation of these mutants clearly demonstrates that
MSH-dependent damage response can operate independently
of the repair function. This result argues against the initia-
tion of futile repair cycles, though we cannot exclude that
Nucleic Acids Research, 2006, Vol. 34, No. 8 2183such a mechanism may have an additional contribution to
MMR-dependent cell death response. An increasing body
of evidence is emerging that suggests a direct role for
MMR-dependent apoptosis. Due to their separate functional
requirements, MMR mutations that promote carcinogenesis
may not predict the response to chemotherapy, and vice
versa. We present the ﬁrst report on the role of DNA ﬂexibility
and speciﬁc protein–DNA interactions as signiﬁcant con-
tributors in the MMR-dependent induction of cell death.
Apart from a general mechanistic understanding, the knowl-
edge on how certain MMR defects modulate the response
to chemotherapeutics will allow a more conscientious choice
of cancer treatment.
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